Terms: = Breast cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Treatment
1511 results:
1. Activation of the MEK/erk Pathway Mediates the Inhibitory Effects of Silvestrol on Nasopharyngeal Carcinoma Cells via RAP1A, HK2, and GADD45A.
Yu LR; Han XZ; Tang YZ; Liu D; Luo XQ; Qiu XW; Feng J; Yuan WX; Ding JY
Front Biosci (Landmark Ed); 2024 Apr; 29(4):160. PubMed ID: 38682208
[TBL] [Abstract] [Full Text] [Related]
2. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC
BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389
[TBL] [Abstract] [Full Text] [Related]
3. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent erk1/2 Inhibitors.
Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
[TBL] [Abstract] [Full Text] [Related]
4. SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target.
Li Y; Yang W; Liu C; Zhou S; Liu X; Zhang T; Wu L; Li X; Zhang J; Chang E
Int Immunopharmacol; 2024 May; 132():111918. PubMed ID: 38537539
[TBL] [Abstract] [Full Text] [Related]
5. Estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines.
Priyanka HP; Pratap UP; Nair RS; Vasantharekha R; ThyagaRajan S
Med Oncol; 2024 Mar; 41(5):92. PubMed ID: 38526769
[TBL] [Abstract] [Full Text] [Related]
6. EPAC inhibitor suppresses angiogenesis and tumor growth of triple-negative breast cancer.
Li Z; Liu Q; Cai Y; Ye N; He Z; Yao Y; Ding Y; Wang P; Qi C; Zheng L; Wang L; Zhou J; Zhang QQ
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167114. PubMed ID: 38447883
[TBL] [Abstract] [Full Text] [Related]
7. Phloretin Inhibits the Proliferation of breast cancer Cells Through the Down-regulation of Estrogen Receptor α.
Jang SY; Kim J; Hong E; Yang YJ; Na Y; Yeom CH; Park S
Anticancer Res; 2024 Mar; 44(3):1109-1120. PubMed ID: 38423666
[TBL] [Abstract] [Full Text] [Related]
8. The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast.
Pandithar S; Galke D; Akume A; Belyakov A; Lomonaco D; Guerra AA; Park J; Reff O; Jin K
Mol Biol Rep; 2024 Feb; 51(1):331. PubMed ID: 38393465
[TBL] [Abstract] [Full Text] [Related]
9. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
10. The antipsychotic drug pimozide promotes apoptosis through the RAF/erk pathway and enhances autophagy in breast cancer cells.
Jiang G; Zhou X; Hu Y; Tan X; Wang D; Yang L; Zhang Q; Liu S
Cancer Biol Ther; 2024 Dec; 25(1):2302413. PubMed ID: 38356266
[TBL] [Abstract] [Full Text] [Related]
11. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating erk signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
12. Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises.
Ahmad J; Ahamad J; Algahtani MS; Garg A; Shahzad N; Ahmad MZ; Imam SS
Expert Opin Drug Deliv; 2024 Feb; 21(2):229-244. PubMed ID: 38344809
[TBL] [Abstract] [Full Text] [Related]
13. ARHGAP6 Suppresses breast cancer Tumor Growth by Promoting Ferroptosis via RhoA-ROCK1-p38 MAPK Signaling.
Chen X; Zhu J; Li X; Chen J; Zhou Z; Fan X; Liang R; Liu H; Zhu D
Front Biosci (Landmark Ed); 2024 Jan; 29(1):6. PubMed ID: 38287795
[TBL] [Abstract] [Full Text] [Related]
14. Anticancer effect of zoledronic acid in endocrine-resistant breast cancer cells via HER-2 signaling.
Adchariyasakulchai P; Sakunrangsit N; Chokyakorn S; Suksanong C; Ketchart W
Biomed Pharmacother; 2024 Feb; 171():116142. PubMed ID: 38198953
[TBL] [Abstract] [Full Text] [Related]
15. Irradiated Cell-derived Exosomes Enhance Cell Proliferation and Radioresistance
Dong Y; Tamari K; Kishigami M; Katsuki S; Minami K; Tatekawa S; Shimizu S; Koizumi M; Ogawa K
Cancer Genomics Proteomics; 2024; 21(1):12-17. PubMed ID: 38151290
[TBL] [Abstract] [Full Text] [Related]
16. SLC35A2 expression drives breast cancer progression via erk pathway activation.
Yang X; Tao Y; Xu Y; Cai W; Shao Q
FEBS J; 2024 Apr; 291(7):1483-1505. PubMed ID: 38143314
[TBL] [Abstract] [Full Text] [Related]
17. Metal-Organic Framework-Based Nano-Activators Facilitating Microwave Combined Therapy via a Divide-and-Conquer Tactic for Triple-Negative breast cancer.
Wu Q; Tan L; Ren X; Fu C; Chen Z; Ren J; Ma T; Meng X
ACS Nano; 2023 Dec; 17(24):25575-25590. PubMed ID: 38095158
[TBL] [Abstract] [Full Text] [Related]
18. CD147 promotes breast cancer migration and invasion by inducing epithelial-mesenchymal transition via the MAPK/erk signaling pathway.
Li F; Wang J; Yan YQ; Bai CZ; Guo JQ
BMC Cancer; 2023 Dec; 23(1):1214. PubMed ID: 38066486
[TBL] [Abstract] [Full Text] [Related]
19. Proliferation, Migration and Invasion of breast cancer Cell Lines Are Inhibited by 1,5-Disubstituted Tetrazol-1,2,3-triazole Hybrids through Interaction with p53.
Moreno-Perea M; Suárez-Castro A; Fraire-Soto I; Sifuentes-Padilla JL; Gutiérrez-Hernández R; Reyes-Estrada CA; López-Hernández Y; Cortés-García CJ; Chacón-García L; Granados-López AJ; López JA
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005322
[TBL] [Abstract] [Full Text] [Related]
20. Unraveling Connective Tissue Growth Factor as a Therapeutic Target and Assessing Kahweol as a Potential Drug Candidate in Triple-Negative breast cancer treatment.
Lee JH; Kim J; Kim HS; Kang YJ
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003505
[TBL] [Abstract] [Full Text] [Related]
[Next]
